SBIR/STTR Research Award
SBIR TOPIC 307: NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOLKIT FOR CANCER DI
Award amount
$1,499,971Program and phase
SBIR · Phase IIAward year
2013Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CELLSIGHT TECHNOLOGIES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- E3UQXACGFR43
- Solicitation number
- Not reported
- Topic code
- NCI
Research abstract
Not Available
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Imaging intracerebral and systemic T cell immunity in patients with Alzheimer's disease using 18F-F-AraG
- SBIR PHASE II - TOPIC 396 - IMAGING FOR CANCER IMMUNOTHERAPIES
- SBIR PHASE I TOPIC 396 EVALUATION OF [18F]F-ARAG, A T CELL-SPECIFIC PET AGENT, AS AN IMAGING BIOMARKER PREDICTIVE OF RESPONSE TO IMMUNOTHERAPIES - MOONSHOT
- Topic 376: A noninvasive PET imaging strategy for longitudinal monitoring of immune contexture in the tumor microenvironmen
- Monitoring immune response to immunotherapies in cancer patients with VisAcT PET tracer
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
7 SBIR/STTR records share this UEI (2011–2025). Reported award amounts total $7,254,593. Reported amounts are not federal obligations.
Phases: Phase II, Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services